-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[June 3, 2021/Medical Information List] GlaxoSmithKline's Zofran safety lawsuit was won; Jiangxi started its first municipal mass purchase; Roche's "Otuzumab" was approved for listing in China.
[June 3, 2021/Medical Information List] Daily fresh medicines and medical news, speed reading and you will pay attention to it together!
Part1 Policy Brief
Part1 policy briefing Part1 policy briefingThe "Eight Provinces and Two Districts" inter-provincial alliance drug procurement officially launched!
The "Eight Provinces and Two Districts" inter-provincial alliance drug procurement officially launched!On June 2, the Heilongjiang Provincial Government Procurement Center issued the "Eight Provinces and Two Districts" Inter-provincial Alliance Drug Centralized Procurement Announcement.
Jiangxi first opened the first municipal-level mass procurement
Jiangxi first opened the first municipal-level mass procurementOn June 3, Jiangxi issued the "Announcement on the Bidding Announcement for the Centralized Purchase of Yichun Medical Consumables in 2021".
Part2 Observation
Part2 Sankei Observation Part2 Sankei ObservationSino Biotech is listed on the Science and Technology Innovation Board today
Sino Biotech is listed on the Science and Technology Innovation Board todayOn June 3, SINOBio, a peptide drug development company, landed on the Science and Technology Innovation Board.
Microbiology completes a new round of financing of nearly 200 million US dollars
Microbiology completes a new round of financing of nearly 200 million US dollarsA few days ago, Microbiology announced that it has officially completed a new round of financing of nearly 200 million US dollars.
Jiang Wei, Bayer's global executive vice president and president of China and Asia Pacific, retires
Jiang Wei, Bayer's global executive vice president and president of China and Asia Pacific, retiresAccording to Bayer China’s public information, based on family arrangements, Mr.
Jimin Pharmaceutical changed its name to Jimin Medical
Jimin Pharmaceutical changed its name to Jimin MedicalRecently, Jimin Pharmaceutical, a listed company, announced that the 15th meeting of the company’s fourth board of directors passed the "Proposal on Changing the Company’s Securities Short Name" and agreed to change the company’s securities short name from "Jimin Pharmaceutical" to "Jimin Pharmaceutical".
GlaxoSmithKline wins Zofran safety lawsuit
GlaxoSmithKline wins Zofran safety lawsuitA few days ago, GlaxoSmithKline won a positive ruling in the Massachusetts District Court following the Zofran case closely.
Youlin Pharmaceutical completes more than 100 million yuan in A+ round of financing
Youlin Pharmaceutical completes more than 100 million yuan in A+ round of financingYoulin Pharmaceutical announced the completion of a round A+ financing of more than 100 million yuan, led by Zhongding Capital, the old shareholder Qianji Capital continued to increase, and Renjin Investment followed the investment.
Part3 Medicine News
Part3 Medicine News Part3 Medicine NewsNovartis Cosentyx receives FDA approval for pediatric plaque psoriasis
Novartis Cosentyx receives FDA approval for pediatric plaque psoriasisAccording to foreign media reports on June 2, the FDA has approved Novartis’ blockbuster product Cosentyx for use in pediatric patients 6 years and older with moderate to severe plaque psoriasis.
U.
U.
Selective JAK inhibitors receive FDA priority review qualification
Selective JAK inhibitors receive FDA priority review qualificationOn June 1, CTI BioPharma announced that the U.
Bioge Bio's bifunctional fusion protein obtained FDA clinical approval
Bioge Bio's bifunctional fusion protein obtained FDA clinical approvalAccording to news on June 2nd, Boge Biosciences recently announced that the US FDA has approved its self-developed PD-L1/TGF-β bifunctional fusion protein new drug clinical trial application for clinical trials in the United States.
NASH new drug is accredited by FDA fast track
NASH new drug is accredited by FDA fast trackOn June 2, Boehringer Ingelheim and Zealand Pharma jointly announced that the FDA has granted GLP-1/glucagon receptor dual agonist BI 456906 fast track designation for adult non-alcoholic steatohepatitis.
Wanfu's new crown antigen self-test products have completed the EU CE certification
Wanfu's new crown antigen self-test products have completed the EU CE certificationOn June 3, Wanfu Biotechnology issued an announcement stating that it had recently completed the EU CE certification of the new coronavirus antigen self-test products.
One hundred when Myers Squibb Opdivo + Yervoy combination won EU approval
One hundred when Myers Squibb Opdivo + Yervoy combination won EU approval
On June 2, Bristol-Myers Squibb announced that the European Commission had approved the Opdivo+Yervoy combination as the first-line treatment for adult patients with unresectable malignant pleural mesothelioma.
The approval is based on the results of the CheckMate-743 study.
(Sina Pharmaceutical News)
The third indication of Cinda PD-1 was approved as the first-line treatment for squamous NSCLC
The third indication of Cinda PD-1 was approved as the first-line treatment for squamous NSCLC
On June 3, the official website of the State Food and Drug Administration showed that the innovative PD-1 inhibitor Sintilimab injection jointly developed by Cinda Biotech and Eli Lilly for the first-line treatment of squamous non-small cell lung cancer officially obtained a new indication NMPA approved, this is the third indication for the product to be approved.
(Medical Rubik's Cube Info)
Betta Pharmaceuticals officially approved the indications for postoperative adjuvant treatment of "Icotinib"
Betta Pharmaceuticals officially approved the indications for postoperative adjuvant treatment of "Icotinib"
On June 3, NMPA issued an approval document, and Betta Pharmaceuticals' new indications for postoperative adjuvant treatment of icotinib were approved for marketing.
This is the third approved indication for icotinib.
It is reported that Icotinib is my country's first small molecule targeted anticancer drug with independent intellectual property rights independently developed by Betta.
(Insight database)
Roche's "Otuzumab" was approved for listing in China
Roche's "Otuzumab" was approved for listing in China
On June 3, Roche's new generation of anti-CD20 monoclonal antibody, Otuzumab, was formally approved by NMPA, combined with chemotherapy, for newly-treated adult patients with stage II and large masses, stage III or IV follicular lymphoma , The subsequent monotherapy maintenance treatment for patients who achieve at least partial remission.
(Sina Pharmaceutical News)
Teyi Pharmaceutical Metronidazole Tablets and Clindamycin Hydrochloride Capsules Passed the Consistency Evaluation
Teyi Pharmaceutical Metronidazole Tablets and Clindamycin Hydrochloride Capsules Passed the Consistency Evaluation
On June 3, Teyi Pharmaceutical announced that the "Metronidazole Tablets" and "Clindamycin Hydrochloride Capsules" recently approved and issued by the National Medical Products Administration of the "Drug Supplementary Application Approval Notice", after review, the above The drug passed the quality and efficacy consistency evaluation of generic drugs.
Metronidazole tablets are used to treat and prevent infections identified or suspected to be caused by anaerobic bacteria; Clindamycin Hydrochloride capsules are mainly used for sensitive strains such as Streptococcus, Staphylococcus and anaerobes.
Infectious diseases.
(Announcement of Special One Pharmaceutical)
